Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data. [electronic resource]
Producer: 20190606Description: 329-334 p. digitalISSN:- 1432-1041
- CTLA-4 Antigen -- antagonists & inhibitors
- Clinical Trials as Topic
- Female
- Humans
- Imidazoles -- administration & dosage
- Ipilimumab -- administration & dosage
- Kaplan-Meier Estimate
- Male
- Melanoma -- drug therapy
- Middle Aged
- Oximes -- administration & dosage
- Poland
- Proto-Oncogene Proteins B-raf -- antagonists & inhibitors
- Retrospective Studies
- Treatment Outcome
- Vemurafenib -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Observational Study
There are no comments on this title.
Log in to your account to post a comment.